On a relative basis, the stock has outperformed the S&P 500 by 0.84% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.26% in the last 1 week, and is up 5.24% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 3.23% and the 50-Day Moving Average is 4.71%.
Baxter International (NYSE:BAX): The stock opened at $47.08 on Friday but the bulls could not build on the opening and the stock topped out at $47.20 for the day. The stock traded down to $46.56 during the day, due to lack of any buying support eventually closed down at $46.77 with a loss of -0.38% for the day. The stock had closed at $46.95 on the previous day. The total traded volume was 2,961,651 shares.
The company Insiders own 1.08% of Baxter International shares according to the proxy statements. Institutional Investors own 85.28% of Baxter International shares. During last six month period, the net percent change held by insiders has seen a change of -23.18%. In a related news, Almeida Jose E, CEO of Baxter International Inc had purchased 11,691 shares on May 23, 2016 in a transaction. The price per share was $42.75 and the total amount of the disclosed transaction was $499,790.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.